Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) is a clinical-stage pharmaceutical company focused on developing small molecule therapeutics for endocrine diseases and endocrine-related tumors. The company's revenue model is based on future product sales, as Crinetics has not yet generated meaningful commercial revenue and funds operations through equity offerings, including its 2024 Sales Agreement dated June 21, 2024. Pipeline programs target conditions including acromegaly, ACTH-Dependent Cushing's Syndrome (ADCS), and congenital adrenal hyperplasia (CAH), among other endocrine disorders. Crinetics is incorporated in Delaware and lists its common stock on the Nasdaq Global Select Market. As of February 13, 2026, the company had shares outstanding with a common stock par value of $0.001 per share. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $28.76 per share on that date. The company operates as a pre-commercial biopharmaceutical entity, relying on capital markets to fund research and development.

Revenue model

Pre-commercial stage; no significant product revenue disclosed in the filing excerpts. Capital is raised through equity offerings, including the 2024 Sales Agreement with sales agents dated June 21, 2024.

Products and services

Small molecule drug candidates targeting endocrine diseases including acromegaly, ACTH-Dependent Cushing's Syndrome (ADCS), and congenital adrenal hyperplasia (CAH). Pipeline compounds address hormone pathways including ACTH (adrenocorticotrophic hormone) and androstenedione (A4).

Customers and end markets

End markets are patients with rare endocrine disorders including acromegaly, Cushing's syndrome, and congenital adrenal hyperplasia. No commercial customers disclosed in the filing excerpts.

Value-chain role

Drug developer; pre-commercial stage biopharmaceutical company conducting clinical development of proprietary small molecule compounds.

Geographic exposure

Incorporated in Delaware; listed on Nasdaq Global Select Market. No geographic revenue breakdown available from the filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Avidity Biosciences, Inc. Cogent Biosciences Inc Emergent BioSolutions Inc Enanta Pharmaceuticals Inc Forma Therapeutics Holdings, Inc. ImmunoGen, Inc. Madrigal Pharmaceuticals Inc Morphic Holding, Inc. REGENXBIO Inc.